Education 【 display / non-display 】

Education 【 display / non-display 】

• 2015

  -

  2020

  Sapporo Medical University   医学部   大学院医学研究科  

• 2004

  -

  2010

  Sapporo Medical University   医学部   医学科  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 2020.09   Sapporo Medical University   PhD

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2022.09

  -

  Now

  Sapporo Medical University   放射線医学講座   助教

• 2019.04

  -

  2022.08

  KKR札幌医療センター   放射線科  

• 2013.04

  -

  2019.03

  札幌医科大学附属病院   放射線治療科   診療医、研究員

• 2011.04

  -

  2012.03

  札幌医科大学附属病院   初期臨床研修医

• 2011.04

  -

  2012.03

  帯広厚生病院   初期臨床研修医

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Radiology   放射線腫瘍学

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   放射線医学講座   助教  

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Prediction of late adverse events in pelvic cancer patients receiving definitive radiotherapy using radiation-induced gamma-H2AX foci assay.

  Masanori Someya, Tomokazu Hasegawa, Asako J Nakamura, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Sho Mafune, Yutaro Ikeuchi, Hiroshi Tauchi, Koh-Ichi Sakata

  Journal of radiation research   64 ( 6 ) 948 - 953  2023.11  [International journal]

  　View Summary

  Radiation can induce DNA double-stranded breaks, which are typically detected by the fluorescence of phosphorylated histone H2AX. In this study, we examined the usefulness of the dynamics of radiation-induced gamma-H2AX foci of peripheral blood lymphocytes (PBLs), as a marker of DNA repair ability, in predicting late adverse events from radiotherapy. A total of 46 patients with cervical, vaginal and anal canal cancers treated with radical radiotherapy between 2014 and 2019 were included in this analysis. Concurrent chemotherapy was administered in 36 cases (78.3%). Peripheral blood was obtained before treatment, and then irradiated ex vivo with 1 Gy X-ray. The ratio of radiation-induced gamma-H2AX foci in PBLs measured at 30 min and at 4 h was defined as the foci decay ratio (FDR). With a median follow-up of 54 months, 9 patients (19.6%) were observed to have late genitourinary or gastrointestinal (GU/GI) toxicity. The FDR ranged from 0.51 to 0.74 (median 0.59), with a significantly higher incidence of Grade 1 or higher late adverse events in the FDR ≥ 0.59 group. In multivariate analysis, FDR ≥ 0.59 and hypertension also emerged as significant factors associated with the development of late toxicities. Overall, our results suggest that measurement of radiation-induced gamma-H2AX foci in PBLs may predict the risk of late GU/GI toxicities from chemoradiotherapy, which can enable tailoring the radiation dose to minimize adverse effects.

  DOI PubMed

• 化学放射線+免疫療法を行った3期NSCLCにおける、末梢血リンパ細胞のTCRレパトア解析

  染谷 正則, 長谷川 智一, 北川 未央, 土屋 高旭, 後町 俊夫, 眞船 翔, 金関 貴幸, 蒔田 芹奈, 鳥越 俊彦, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   O46 - 3  2023.10

• Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.

  Yutaro Ikeuchi, Masanori Someya, Tomokazu Hasegawa, Masato Saito, Shoh Mafune, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Yoshihiko Hirohashi, Toshihiko Torigoe, Naoki Hirokawa, Akihiro Miyazaki, Koh-Ichi Sakata

  Medical molecular morphology    2023.07  [Domestic journal]

  　View Summary

  Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of proteins involved in tumor immunity on the outcomes of combined IACRT and surgery for oral cancer. We examined CD8 + and FoxP3 + tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on immune cells and tumor cells in pretreatment biopsy samples from 69 patients diagnosed with oral cancer treated with IACRT at our institution during 2000-2020. Patients with abundant CD8 + TILs had significantly better 5-year disease-specific survival (DSS) compared to that of patients with less infiltration of these cells (P = 0.016). Patients with higher FoxP3 + T-cells invasion had significantly better DSS compared to that of less FoxP3 (P = 0.005). Patients with high PD-L1 expression in tumor cells and immune cells had significantly better DSS than that of patients with low PD-L1 expression in these cells (P = 0.009 and P = 0.025, respectively). Collectively, these results suggest that the tumor immune microenvironment could affect outcomes of IACRT treatment in oral cancer.

  DOI PubMed

• Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy.

  Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Masashi Idogawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

  Medical molecular morphology   56 ( 1 ) 38 - 45  2023.03  [Domestic journal]

  　View Summary

  Resistance of cervical cancer to radiotherapy with concurrent chemotherapy (CCRT) results in a poor prognosis. To identify new biomarkers for predicting the treatment response and prognosis, we explored exosomal microRNA (miRNA) expression signatures associated with the outcome of cervical cancer patients treated with CCRT. Exosomes were isolated from the plasma of 45 patients prior to CCRT during 2014-2020, and miRNA analysis was performed by next-generation sequencing. At a median follow-up of 38 months, 26 patients were recurrence free, 15 patients had died of the disease, and 4 patients received salvage chemotherapy due to distant metastasis. Of the 2522 miRNAs detected, 9 (miR-148a-5p, 1915-3p, 3960, 183-5p, 196b-5p, 200c-3p, 182-5p, 374a-5p, and 431-5p) showed differential expression between the recurrence-free and recurrence groups. Patients were divided into high- and low-risk groups according to the cutoff of the miRNAs-based risk score calculated from respective expression levels. The high-risk group had significantly worse disease-specific survival than the low-risk group (p < 0.001). In addition, miR-374a-5p and miR-431-5p expression showed a weak inverse correlation with tumor-infiltrating CD8+ and FOXP3+ T cells, suggesting a potential inhibitory effect on CCRT by suppressing tumor immunity. This miRNA signature could improve non-invasive monitoring and personalized treatment for cervical cancer.

  DOI PubMed

• Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.

  Masanori Someya, Serina Tokita, Takayuki Kanaseki, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yoh Kozuka, Shoh Mafune, Yutaro Ikeuchi, Mamoru Takahashi, Keigo Moniwa, Kazuhiko Matsuo, Tadashi Hasegawa, Toshihiko Torigoe, Koh-Ichi Sakata

  Cancer science   113 ( 12 ) 4394 - 4400  2022.12  [International journal]

  　View Summary

  Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation therapy has improved the overall survival of patients with NSCLC, the synergistic action mechanisms of CRT and immunotherapy on T cells remain unclear. In addition, there is a paucity of reliable biomarkers to predict clinical responses to therapy. In this study, we analyzed T-cell receptor (TCR) sequences in the peripheral blood of five patients with NSCLC. T-cell receptor analysis was undertaken before treatment, after CRT, and after PD-L1 blockade. Notably, we observed the expansion and alteration of the dominant T-cell clonotypes in all cases with a complete response. In contrast, neither expansion nor alteration of the TCR repertoire was observed in cases with progressive disease. T cell expansion was initiated after CRT and was further enhanced after PD-L1 blockade. Our findings suggest the systemic effect of CRT on circulating T cells in addition to the curative effect on limited tumor sites. Dynamic changes in circulating T-cell clonotypes could have a prognostic significance for combined CRT and PD-L1 blockade.

  DOI PubMed

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 化学放射線療法+免疫療法を行った3期切除不能非小細胞肺癌における,末梢血リンパ細胞のTCRレパトア解析

  染谷正則, 長谷川智一, 北川未央, 土屋高旭, 眞船翔, 後町俊夫, 池内佑太郎, 金関貴幸, 鳥越俊彦, 坂田耕一

  日本免疫治療学会学術集会プログラム・抄録集   20th  2023

  J-GLOBAL

• 血中エクソソームmiRNAを用いた子宮頸癌の治療効果予測

  染谷正則, 土屋高旭, 福島悠希, 池内佑太郎, 眞船翔, 小塚陽, 北川未央, 後町俊夫, 坂田耕一

  日本免疫治療学会学術集会プログラム・抄録集   19th  2022

  J-GLOBAL

• 子宮頸癌根治照射症例におけるCD8の浸潤形式と予後との関連

  染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  59回   O37 - 7  2021.10

• 根治放射線療を行った進行期子宮頸癌症例における腫瘍免疫と予後の関連

  染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 高田 優, 中田 健生, 堀 正和, 三浦 勝利, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  58回   O16 - 4  2020.10

• 子宮頸癌の放射線治療成績と末梢血リンパ球のDNA-PK活性の関係

  染谷 正則, 松本 健一, 福島 悠希, 後町 俊夫, 土屋 高旭, 長谷川 智一, 北川 未央, 堀 正和, 中田 健生, 坂田 耕一

  Japanese Journal of Radiology ( (公社)日本医学放射線学会 )  36 ( Suppl. ) 11 - 11  2018.02

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• Practical application of individualized radiotherapy using liquid biopsy

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2021.04

  -

  2024.03

   

  染谷 正則, 池内 佑太郎, 小塚 陽, 後町 俊夫

  　View Summary

  ＜目的＞治療効果向上と有害事象軽減を目指した「個別化放射線治療」を実践するために、局所進行悪性腫瘍に対し、末梢リンパ球や血中の腫瘍由来エクソソームに存在する、mRNAやmiRNAの発現パターンを調べ、放射線治療効果を予測する。またDNA修復能の指標として末梢リンパ球の放射線誘発ガンマH2AXフォーカスを測定する事で有害事象を予測する。これらの手法を用いて個々の患者毎の特性に合わせて線量分割や照射体積を調整する。 ＜方法＞以下に示す方法で、末梢血リンパ細胞およびエクソソーム内のmRNA/miRNA発現パターンや末梢血リンパ細胞の放射線誘発ガンマH2AXフォーカス形成能を測定した。 (A) 血漿中からのエクソソームの抽出とRNA分離・発現解析は、QIAGEN社のexoRNeasy plasma kitを用いた。バイオアナライザーを用いてRNA濃度と目的となる２０‐２５塩基配列程度のmiRNAが取れている事を確認した。QIAseq miRNA Library Kitを用いてRNA解析を行なった。これまで子宮頸がん36例からのエクソソーム抽出を行い、再発リスクとなる候補miRNAを抽出する。 (B) 末梢血リンパ細胞の放射線誘発ガンマH2AXフォーカス計測は、ex vivoでX線を１Gy照射し、３０分後および４時間後にリンパ球を分離・固定を行い、スライドグラス上で蛍光免疫染色を行い、蛍光顕微鏡下にフォーカス数をカウントし、その変化率を計算してDNA修復能力を数値化する。

• Application of Liquid Biopsy for Personalized Radiation Therapy

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2018.04

  -

  2021.03

   

  Someya Masanori

  　View Summary

  In order to realize "personalized radiotherapy", we used a technique called "liquid biopsy" to examine the nucleic acids and proteins of tumor-derived exosomes in plasma, and applied it to the prediction of radiosensitivity of cancer. Blood samples were collected from a total of 150 patients with cervical, rectal, anal and pancreatic cancers treated with abdominal to pelvic radiotherapy, and plasma and lymphocyte samples were isolated. DNA-PK activity of lymphocytes and radiation-induced gamma H2AX focus was measured, and exosomal microRNA expression analysis in plasma was performed. Based on the results of the treatment outcome and adverse event surveys for each cancer and the results of lymphocyte DNA-PK activity and radiation-induced gamma-H2AX focus measurements, we showed that exosomal microRNAs in plasma are useful for predicting the effects of radiotherapy and that lymphocyte DNA-PK activity may be useful for predicting late adverse events after radiotherapy.

• Prediction of local tumor control and acute radiation toxicity in pelvic cancer patients using lymphocyte biomarker.

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2015.04

  -

  2018.03

   

  Someya Masanori

  　View Summary

  To predict individual treatment effects and acute toxicity of patients who underwent pelvic radiation therapy, blood lymphocytes were collected from 141 patients who underwent definitive radiation therapy for non metastatic prostate cancer at our hospital, we measured the DNA-dependent protein kinase (DNA-PK) activity, which is considered to be involved in DNA damage repair, and the expression analysis of microRNA-410, 221 and 99a. As a result, we showed that the DNA-PK activity of lymphocytes was a significant predictor of biochemical relapse in prostate cancer patients and that a combination of miRNA-410 and 221 predicted acute gastrointestinal toxicities with higher accuracy than conventional dose-volume histogram analysis.